MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2016 International Congress

    Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice

    S.J. LoRusso, B. Ouyang, B.R. Barton (Chicago, IL, USA)

    Objective: To evaluate the real-world response of patients who are converted from IR CD-LD and SR CD-LD to ER CD-LD in an academic practice. Background:…
  • 2016 International Congress

    Lessons-experienced in the creation of a global public-private consortium with the goal of advancing treatments that hold most potential for delayed disease progression in Parkinson’s disease – Critical path for Parkinson’s (CPP)

    V.D. Kern, D.T. Stephenson, K. Romero, E. Avilés, S.T. Broadbent, S.P. Arneric, L. Barbieri, S. Ford, A. Roach (Tucson, AZ, USA)

    Objective: The path is summarized that led to the creation of a global public-private-partnership uniting an international non-profit charity, Parkinson's UK, a global non-profit organization,…
  • 2016 International Congress

    Extended-release carbidopa-levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson’s disease

    S. Gupta, S. Khanna, S. Kell, R. Rubens (Hayward, CA, USA)

    Objective: Evaluate the efficacy and dosing of IPX066 in patient groups taking concomitant Parkinson's disease (PD) medication, using post hoc subgroup analyses. Background: IPX066 is…
  • 2016 International Congress

    The dopamine agonist withdrawal syndrome rating scale (DAWS-RS): Initial development of a new non-motor scale

    L.S. Croll, K.M. Montgomery, C.V. Kulick, M.J. Nirenberg (New York, NY, USA)

    Objective: To describe the development of the dopamine agonist withdrawal syndrome (DAWS) rating scale (DAWS-RS), a new questionnaire designed to evaluate the symptoms, severity, and…
  • 2016 International Congress

    Reflex saccades changes can estimate long-term symptom progression in DBS STN and MED Parkinson’s disease patients (PD)

    S. Szlufik, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Koziorowski (Warsaw, Poland)

    Objective: The aim of this study was to evaluate the impact of STN DBS on RS parameters in PD. We have compared disease progression in…
  • 2016 International Congress

    Long-term effects of levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease patients: Dutch multicenter retrospective cohort study

    H.R. Moes, J. Groenendal-Laurensse, M. Drent, G. Tissingh, T. van Laar (Groningen, Netherlands)

    Objective: To determine the long-term outcomes of levodopa/carbidopa intestinal gel infusion (LCIG) in advanced Parkinson's disease (PD) patients. Background: LCIG was introduced in the Netherlands…
  • 2016 International Congress

    The impact of STN DBS on kinetic tremor in Parkinson’s disease patients

    S. Szlufik, M. Szumilas, J. Dutkiewicz, D. Koziorowski, T. Mandat, E. Slubowska (Warsaw, Poland)

    Objective: The aim of the study is to evaluate the impact of STN DBS on kinetic tremor in PD patients in comparison to pharmacologically treated…
  • 2016 International Congress

    Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease – A randomized, crossover infusion study

    M. Senek, D. Nyholm (Uppsala, Sweden)

    Objective: To compare the systemic levodopa exposure during administration of levodopa-entacapone-carbidopa (LECIG) intestinal gel with levodopa-carbidopa intestinal gel (LCIG) in advanced Parkinson's disease (PD) patients.…
  • 2016 International Congress

    Predicting therapeutic effects of atomoxetine and citalopram on response inhibition in Parkinson’s disease

    J.B. Rowe, C. Rae, C. Nombela, T. Ham, P. Vazquez, I. Coyle-Gilchrist, C.R. Housden, B.J. Sahakian, T.W. Robbins, Z. Yes (Cambridge, United Kingdom)

    Objective: (1) To reassess the behavioral impact of novel noradrenergic (atomoxetine) and serotonergic (citalopram) therapies for impulsivity and (2) to develop predictive models to identify…
  • 2016 International Congress

    Diurnal variation of levodopa plasma concentration in patients with Parkinson’s disease

    M. Nagai, M. Kubo, H. Iwaki, R. Ando, H. Yabe, N. Nishikawa, M. Nomoto (Ehime, Japan)

    Objective: We analyzed diurnal variation of levodopa plasma concentration in large number of patients with Parkinson's disease (PD) to clarify the pattern of diurnal variation.…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley